Your browser doesn't support javascript.
loading
Proof­of­concept study to quantify changes in intestinal loads of KPC-producing Klebsiella pneumoniae in colonised patients following selective digestive decontamination with oral gentamicin.
Pérez-Nadales, Elena; Natera, Alejandra M; Recio-Rufíán, Manuel; Guzmán-Puche, Julia; Cano, Ángela; Frutos-Adame, Azahara; Castón, Juan José; Elías-López, Cristina; Romero-Saldaña, Manuel; López-Cerero, Lorena; Martínez-Martínez, Luis; Torre-Cisneros, Julián.
  • Pérez-Nadales E; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lif
  • Natera AM; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lifestyles, Innovation and Health (GA-16) Groups, Maimonides Biomedical Research Institute of Cordoba (IMI
  • Recio-Rufíán M; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lifestyles, Innovation and Health (GA-16) Groups, Maimonides Biomedical Research Institute of Cordoba (IMI
  • Guzmán-Puche J; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lif
  • Cano Á; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lif
  • Frutos-Adame A; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lifestyles, Innovation and Health (GA-16) Groups, Maimonides Biomedical Research Institute of Cordoba (IMIBIC/Reina Sofía University Hospital/University of Córdoba), Cordoba, Spain.
  • Castón JJ; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lif
  • Elías-López C; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lifestyles, Innovation and Health (GA-16) Groups, Maimonides Biomedical Research Institute of Cordoba (IMI
  • Romero-Saldaña M; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lifestyles, Innovation and Health (GA-16) Groups, Maimonides Biomedical Research Institute of Cordoba (IMIBIC/Reina Sofía University Hospital/University of Córdoba), Cordoba, Spain.
  • López-Cerero L; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Clinical Unit of Infectious Diseases and Microbiology, Virgen Macarena University
  • Martínez-Martínez L; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lif
  • Torre-Cisneros J; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Infectious Diseases (GC-03), Clinical and Molecular Microbiology (GC-24), and Lif
J Glob Antimicrob Resist ; 30: 16-22, 2022 09.
Article en En | MEDLINE | ID: mdl-35443207
ABSTRACT

OBJECTIVES:

To monitor quantitatively the extent of intestinal colonisation by KPC-producing Klebsiella pneumoniae (KPC-Kp) in colonised patients who receive selective digestive decontamination (SDD) with oral gentamicin.

METHODS:

We developed a real-time quantitative PCR (qPCR) method for determination of the relative load of blaKPC (RLKPC) within the gut microbiota. Clinical validation was performed using a culture method as the gold standard and receiver operating curve (ROC) analysis. Fifteen patients were observationally and prospectively followed for one year. Clinical, microbiological variables and rectal swab samples were collected at 0 (baseline), 14 and 30 days and monthly thereafter.

RESULTS:

Clinical validation performed on 111 rectal swab samples demonstrated that the PCR method detected 17% more positives than the culture method. ROC curve analysis documented excellent agreement between both methods (area under the curve, 0.96; 95% confidence interval 0.93-0.99). The RLKPC decreased in 6/15 (40%) and 7/12 (58.3%) patients on days 14 and 30, respectively. Persistent eradication was observed in 2/12 (16.7%), 3/9 (33.3%), 4/8 (50%) and 7/8 (87.5%) patients at 1, 3, 6 and 12 months, respectively, with a median time of 150 days (range 30-270) to persistent eradication. Gentamicin-resistant KPC-Kp isolates were identified in 4/15 (26.7%) patients. The rates of infections (57.1% vs. 12.5%, P = 0.119) and deaths (71.4% vs. 0%, P = 0.007) were higher among patients with high baseline RLKPC.

CONCLUSION:

Following SDD, a rapid reduction on intestinal load is observed when the colonising KPC-Kp isolate is susceptible to gentamicin; however, persistent eradication at the end of SDD is low. Intestinal carriage of KPC-Kp persists after three months in about one third of patients.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Klebsiella / Klebsiella pneumoniae Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Klebsiella / Klebsiella pneumoniae Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article